• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Thera (NQ: AXSM )

    91.31 -0.25 (-0.27%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 402,576
    Open 91.51
    Bid (Size) 86.00 (1)
    Ask (Size) 91.40 (1)
    Prev. Close 91.56
    Today's Range 89.23 - 91.51
    52wk Range 55.02 - 98.40
    Shares Outstanding 47,190,970
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
    Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders 
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    What Analysts Are Saying About Axsome Therapeutics Stock
    Via Benzinga

    Performance

    YTD
    +18.49%
    +18.49%
    1 Month
    +3.16%
    +3.16%
    3 Month
    +15.57%
    +15.57%
    6 Month
    +19.02%
    +19.02%
    1 Year
    +29.10%
    +29.10%

    More News

    Read More
    Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Unveiling 14 Analyst Insights On Axsome Therapeutics
    Via Benzinga
    A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 9 Analysts
    Via Benzinga
    Decoding 9 Analyst Evaluations For Axsome Therapeutics
    Via Benzinga
    Should You Buy This Sinking Stock on the Dip?
    Via The Motley Fool
    Axsome Therapeutics to Participate in Investor Conferences in September
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    New Study Reveals How Classical Music Could Revolutionize Depression Care
    Via PressReach
    Exposures Product Safety
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Why Axsome Therapeutics Stock Is Sinking Today
    Via The Motley Fool
    Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth
    Via Investor's Business Daily
    Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
    Via FinancialNewsMedia
    Exposures Product Safety
    Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
    From FN Media Group LLC
    Via GlobeNewswire
    Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
    Via Benzinga
    7 Biotech Stocks to Keep on Your Clinical Radar
    Via InvestorPlace
    Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
    Via Benzinga
    Bull Market and Beyond: 2 Stocks Just Waiting to Soar
    Via The Motley Fool
    Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    The 3 Best Biotech Stocks to Buy in July 2024
    Via InvestorPlace
    3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.